

# Conference schedule

## Thursday 7 July – (morning)

09.00 Foyer/GH001	Registration opens
09.00-10.00 GH014	Early Career Researcher welcome session
10.00-10.20 GH043	<b>Welcome</b> Nick Moberly (CEO, MS Society) Sharon Hier (Patient Representative) Ruth Dobson & Klaus Schmierer (Chairs, MS Frontiers Scientific Committee)
10.20-11.00 GH043	<b>Opening Plenary</b> Melinda Magyari (Danish MS Registry) <b>How real-world data are affecting clinical practice</b>
11.00-11.15 GH001	<b>Break</b>
11.15-13.00 GH043	<b>Parallel sessions 1 and 2</b> <b>Risk factors – are we getting closer to preventing MS?</b> chaired by Ruth Dobson (Queen Mary University of London) and Bruno Gran (University of Nottingham) 11.20 Stephen Sawcer (University of Cambridge) Yes! 11.45 Ruth Dobson (Queen Mary University of London) Yes – but is there a crucial time to intervene? 12.10 Steve Simpson-Yap (University of Melbourne) Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia 12.25 Ben Jacobs (Queen Mary University of London) The ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis. Protocol and baseline results. 12.40 Pavel Loginovic (University of Exeter) A Multiple Sclerosis Genetic Risk Score Improves Prediction of Future Multiple Sclerosis at Time of Diagnosis of Optic Neuritis
GH037	<b>What's new in imaging?</b> chaired by Adam Waldman (University of Edinburgh) and Olga Ciccarelli (University College London) 11.20 Adam Waldman (University of Edinburgh) Measuring inflammation, demyelination and neurodegeneration in MS using MRI and PET 11.45 Axel Petzold (University College London)

# Conference schedule

12.10	The potential for OCT in MS diagnosis and research Amjad AlTokhis (Nottingham University Hospitals NHS Trust) Longitudinal Clinical Study of Patients with White Matter Iron Rims Lesions in Multiple Sclerosis
12.25	James Harper (University of Edinburgh) T1 mapping in early relapsing-remitting Multiple Sclerosis; sensitivity to neurodegenerative change and clinical correlates.
12.40	Alberto Calvi (University College London) Relationship between paramagnetic rim lesions and slowly expanding lesions in people with multiple sclerosis

## Thursday 7 July – (afternoon)

13.00-14.00 Upstairs galleries	Lunch and poster viewing
14.00-15.45 GH043	Parallel sessions 3 and 4 Remyelination and neuroprotection chaired by Don Mahad (University of Edinburgh) and Owain Howell (Swansea University)
14.00	Owain Howell (Swansea University) Neurodegeneration in MS: When, where and how?
14.10	Don Mahad (University of Edinburgh) Enhancing axonal response of mitochondria to demyelination: a novel neuroprotective strategy for MS
14.25	Tanja Kuhlmann (University of Münster) Reasons for impaired remyelination in multiple sclerosis: previous concepts revisited
14.50	Nick Cuniffe (University of Cambridge) Electrophysiological demonstration of a durable remyelinating effect with bexarotene in people with relapsing-remitting multiple sclerosis
15.05	Laura Wagstaff (University of Edinburgh) Using CRISPR/Cas editing to enhance human OPC migration
15.20	Alexandra Nicaise (University of Cambridge) Senescent Neural Stem Cells as Disease Pacemakers in Progressive Multiple Sclerosis
GH037	Trials and therapeutics – are we tackling progression from every angle? chaired by Klaus Schmierer (Queen Mary University of London) and Floriana de Angelis (University College London)
14.00	Emma Tallantyre (Cardiff University)

# Conference schedule

	14.23	Measuring outcomes: designing trials for Progressive MS David Baker (Queen Mary University of London)
	14.46	Targeting Progression: Lessons learned from biological understanding Klaus Schmierer (Queen Mary University of London)
	15.00	The time is now. Tackling MS deterioration in AttackMS and ChariotMS Thomas Williams (University College London)
	15.15	Cardiovascular risk and normalised whole and regional brain volumes: baseline analysis from the MS-STAT2 randomised controlled trial UCL MRI sub-study Steve Simpson-Yap (University of Melbourne)
	15.30	Longitudinal trajectories of diet quality and associations with clinical progression over 7.5 years in an international sample of people with MS Laura Edwards (University of Nottingham)
		Disease modifying therapies and the "lost tribe" of progressive MS
15:45-16.15	Break	
GH001		
16:15-17.00	Spotlight session: The practicalities of getting the patient voice heard	
GH043	Chaired by Anneesa Amjad (Patient and Public Involvement Manager, MS Society)	
17:00-17:45	Conference Debate: We should stop using the labels relapsing remitting, primary progressive and secondary progressive MS	
GH043	Chaired by Martin Duddy (Newcastle Hospitals NHS Foundation Trust)	
	Speaking for the motion: Tarunya Arun (University Hospitals of Coventry and Warwickshire) and Dominic Shadbolt (Patient representative)	
	Speaking against the motion: William Brown (University of Cambridge)	
17:45-18.15	Break	
GH001		
18:15-19:15	Drinks reception and poster judging	
Upper galleries		
19:15-21:00	Gala Dinner	
Sir Stanley Clarke	With Orpheus Male Voice Choir	
Auditorium		

# Conference schedule

## Friday 8 July – (morning)

08:30-09.30 GH043	Spotlight session: Making MS research more representative Chaired by Roxanne Murray (Patient representative) Helen Ford (University of Leeds) Diversity challenges in UK MS research Mitzi Williams (Joi Life Wellness Neurology Centre) Understanding barriers and developing strategies for increasing involvement of people from ethnic minority backgrounds in research
09:30-10.15 GH043	Ian McDonald Memorial Lecture Alan Thompson (University College London) Progressive MS: Conversations, challenges and consensus  Introduced by Michael Hutchinson (University College Dublin)
10:15-10.30 GH001	Break
10:30-12.00 GH037	Parallel sessions 5 and 6 Glia – active players in MS chaired by Yvonne Dombrowski (Queen’s University Belfast) and Irene Molina-Gonzalez (University of Edinburgh)  10:30           Alistair Gamble (University of Glasgow) Lipid-Specific IgMs Enhance CNS Antiviral Defences  10:50           Nicola Hamilton-Whitaker (Kings College London) Understanding how myelin can regulate neuronal function and brain excitability  11:05           Irene Molina-Gonzalez (University of Edinburgh) Astrocyte-Oligodendrocyte interaction drives central nervous system remyelination  11.20           Katie Chapple (University of Glasgow) The myelinic channel system: a highway to the glial-axonal junction and infrastructure for myelin remodelling  11.35           Anna Williams (University of Edinburgh) Oligodendrocyte heterogeneity in MS
GH043	Shaping MS care for the future chaired by Owen Pearson (Swansea University) and Orla Gray (South Eastern Health and Social Care Trust)  10:35           Joela Matthews (Barts Health NHS Trust) Addressing the MS Care Paradox – the practical solutions

# Conference schedule

10:55	Jeff Rodgers (UK MS Register) Impact of smoking cessation on Multiple Sclerosis disease progression
11:05	Agne Straukiene (Torbay and South Devon NHS Trust) Healthy lifestyle MS group clinics and the role of digital technology (MS connect plus app) at Torbay and South Devon NHS Foundation Trust
11:15	Jonathan Hawken (Swansea Bay UHB) Group counselling consultations: The way forward?
11:21	Lauren Taylor (University of Nottingham) Understanding who benefits most from cognitive rehabilitation for multiple sclerosis: a secondary data analysis
11:27	Nicola Vickaryous (Queen Mary University of London) COVID-19 vaccination in pwMS: post v2 and v3 responses
11:33	David Rog (Northern Care Alliance NHS Trust) The UK MS Pregnancy Register: Baseline data from the first fifty participants
11:39	Blanca De Dios Perez (University of Nottingham) Delivering a job retention vocational rehabilitation intervention for people with MS in the community: A single-case series
11:45	Panel Q&A
12:00-12:45	Closing session with Poster Prizes
GH043	Chaired by Klaus Schmierer (Queen Mary University of London) and Ruth Dobson (Queen Mary University of London)
12:45	Lunch On site or available to take away
13:45-14:45	Workshop: Ensuring effective treatments are available to people with MS – addressing the value for money issue Led by Annie Hawton (University of Exeter)